|
|
Vol. 9.30 – 7 October, 2024
|
|
|
|
|
|
|
|
Researchers showed that mice deleted for Dhx36 in the embryonic or neonatal heart develop overt dilated cardiomyopathy, surface ECG alterations related to cardiac impulse propagation, and a lack of a ventricular conduction system. [Nature Communications]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
|
|
Investigators established an in vivo model of cardiac remodeling by transverse aortic narrow and then stimulated a human cardiomyocyte cell line and a human cardiac fibroblast cell line using 1 μmol/L angiotensin II to establish an in vitro model of cardiac hypertrophy and myocardial fibrosis, respectively.
[Molecular and Cellular Biochemistry]
|
|
|
|
|
|
|
|
Researchers demonstrated that Adck2 heterozygous mice exhibited defects from embryonic development, particularly in skeletal muscle. Adck2 heterozygous embryos were 7% smaller in size and displayed signs of delayed development. [Journal of Cachexia Sarcopenia and Muscle]
|
|
|
|
|
|
Scientists investigated the effect of taurine on skeletal muscle glycolysis in pigs. They found through in vivo and in vitro experiments that taurine reduced skeletal muscle glycolysis by inhibiting HIF-1α signaling.
[Journal of Cellular Physiology]
|
|
|
|
|
|
|
|
Investigators propose decreased LRP1 expression in smooth muscle cells to remodel the extracellular matrix enhanced by TGF-β as a potential mechanism of this pleiotropic locus for vascular diseases.
[Circulation Research]
|
|
|
|
|
|
Scientists proved that circSSR1 was down-regulating expression during hypoxia in pulmonary artery smooth muscle cells, and over-expression of circSSR1 inhibit pyroptosis both in vitro and in vivo under hypoxic. [Respiratory Research]
|
|
|
|
|
|
|
|
The authors detail the mechanisms behind myostatin’s function and the various inhibitors that have been tested preclinically and clinically. [Molecular and Cellular Biochemistry]
|
|
|
|
|
|
|
|
Elevai Labs, Inc. announced the filing of two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. [Elevai Labs, Inc.]
|
|
|
|
|
|
|
|
November 6-8, 2024, 2024 London, England, United Kingdom
|
|
|
|
|
|
|
|
|
|
|
The University of Tennessee Health Science Center – Memphis, Tennessee, United States
|
|
|
|
|
|
|
Wellcome Trust – Cambridge, England, United Kingdom
|
|
|
|
|
|
|
Manchester Metropolitan University – Manchester, England, United Kingdom
|
|
|
|
|
|
|
IBSA Foundation for Scientific Research – Lugano, Switzerland
|
|
|
|
|
|
|
University of Minnesota – Twin Cities, Minnesota, United States
|
|
|
|
|
|